Department of Health Sciences, University of Jaén, Jaén, Spain.
Department of Human Anatomy and Embryology, Faculty of Medicine, University of Granada, Granada, Spain.
Expert Opin Biol Ther. 2021 Dec;21(12):1609-1621. doi: 10.1080/14712598.2021.1922666. Epub 2021 May 11.
: Trypsinogen and chymotrypsinogen have been used clinically in tissue repair due to their ability to resolve inflammatory symptoms. Recently, novel evidence has supported the anti-tumourigenic potential of a mixture of trypsinogen and chymotrypsinogen.: First, we analyze the structure of these proteases and the effects of pancreatic proteinases on tissue repair, inflammation and the immune system. Second, we summarize studies that provided evidence of the effects of pancreatic (pro)enzymes on tumor cells both and and some successful clinical applications of pancreatic (pro)enzymes. Finally, we study pancreatic (pro)enzymes potential molecular targets, such as the proteinase-activated receptors (PARs).: This novel therapy has been shown to have effective antitumor effects. Treatment with these (pro) enzymes sensitizes Cancer Stem Cells (CSCs) which may allow chemotherapy and radiotherapy to be more effective, which could positively affect the recovery of cancer patients.
胰蛋白酶原和糜蛋白酶原因其能够缓解炎症症状而在组织修复中得到临床应用。最近，新的证据支持胰蛋白酶原和糜蛋白酶原混合物的抗肿瘤潜力。
首先，我们分析这些蛋白酶的结构以及胰腺蛋白酶对组织修复、炎症和免疫系统的影响。其次，我们总结了一些研究，这些研究提供了胰腺（前）酶对肿瘤细胞的影响的证据，以及胰腺（前）酶的一些成功的临床应用。最后，我们研究了胰腺（前）酶的潜在分子靶点，如蛋白酶激活受体（PARs）。
这种新的治疗方法已被证明具有有效的抗肿瘤作用。用这些（前）酶处理可以使癌症干细胞（CSCs）敏感化，这可能使化疗和放疗更有效，这可能对癌症患者的康复产生积极影响。
